ReviewInternational journal of nanomedicine2026
Nanomedicine for Benign Prostatic Hyperplasia: Pathological Axes and Translational Evidence.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign prostatic hyperplasia (BPH) is heterogeneous, and lower urinary tract symptoms also depend on smooth-muscle tone, outlet mechanics and bladder function. Nanomedicine research spans formulation development, animal experiments and limited clinical exploration, but these stages do not establish a continuous chain from delivery to durable patient benefit. This critical narrative review combines a structured PubMed update search through September 7, 2026 with descriptive evidence mapping. Historical search strings were unavailable; the update queries and records are retained, and retrieved records are distinguished from the curated study inventory. We organize relevant biology into inflammatory, hormonal-metabolic and fibrotic/extracellular-matrix axes and propose a barrier-signal-payload-feedback framework. The evidence tiers and decision gates are proposed analytical tools, not validated clinical classifications or regulatory pathways. Source-checked reports predominantly assess formulation properties, systemic exposure, organ size, histology or molecular outcomes. Healthy-volunteer pharmacokinetics does not constitute BPH therapeutic evidence, and whole-prostate exposure does not establish delivery to nodules or specific cells. A small nanomicellar-curcumin trial provides an early symptom signal below its study-defined clinical-importance threshold. Animal saline-loaded urine measurements and short-term cystometry from an adjacent local hydrogel represent different functional outcomes and cannot be equated with durable clinical benefit. The three-axis framework also does not establish which process initiates early nodular formation. Progress requires reproducible disease-state stratification, quantitative lesion delivery with prespecified target engagement, and sustained functional benefit supported by chronic safety and manufacturability. Added formulation complexity is justified only by measurable incremental value over simpler formulations, free payloads or appropriate standard treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.